207 related articles for article (PubMed ID: 22639159)
1. Mechanisms of immune evasion by gliomas.
Rolle CE; Sengupta S; Lesniak MS
Adv Exp Med Biol; 2012; 746():53-76. PubMed ID: 22639159
[TBL] [Abstract][Full Text] [Related]
2. The role of regulatory T-cells in glioma immunology.
Ooi YC; Tran P; Ung N; Thill K; Trang A; Fong BM; Nagasawa DT; Lim M; Yang I
Clin Neurol Neurosurg; 2014 Apr; 119():125-32. PubMed ID: 24582432
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of tolerance induced by transforming growth factor-beta-treated antigen-presenting cells: CD8 regulatory T cells inhibit the effector phase of the immune response in primed mice through a mechanism involving Fas ligand.
Kosiewicz MM; Alard P; Liang S; Clark SL
Int Immunol; 2004 May; 16(5):697-706. PubMed ID: 15096489
[TBL] [Abstract][Full Text] [Related]
4. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses.
Hussain SF; Yang D; Suki D; Aldape K; Grimm E; Heimberger AB
Neuro Oncol; 2006 Jul; 8(3):261-79. PubMed ID: 16775224
[TBL] [Abstract][Full Text] [Related]
5. Induction of macrophagic prostaglandin E2 synthesis by glioma cells.
Nakano Y; Kuroda E; Kito T; Yokota A; Yamashita U
J Neurosurg; 2006 Apr; 104(4):574-82. PubMed ID: 16619662
[TBL] [Abstract][Full Text] [Related]
6. Immune defects observed in patients with primary malignant brain tumors.
Dix AR; Brooks WH; Roszman TL; Morford LA
J Neuroimmunol; 1999 Dec; 100(1-2):216-32. PubMed ID: 10695732
[TBL] [Abstract][Full Text] [Related]
7. Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines.
Ueda R; Fujita M; Zhu X; Sasaki K; Kastenhuber ER; Kohanbash G; McDonald HA; Harper J; Lonning S; Okada H
Clin Cancer Res; 2009 Nov; 15(21):6551-9. PubMed ID: 19861464
[TBL] [Abstract][Full Text] [Related]
8. Site-specific anti-tumor immunity: differences in DC function, TGF-beta production and numbers of intratumoral Foxp3+ Treg.
Biollaz G; Bernasconi L; Cretton C; Püntener U; Frei K; Fontana A; Suter T
Eur J Immunol; 2009 May; 39(5):1323-33. PubMed ID: 19337997
[TBL] [Abstract][Full Text] [Related]
9. Endothelin B receptor promotes the proliferation and immune escape of malignant gliomas.
Pan DS; Feng SZ; Cao P; Li JJ
Artif Cells Nanomed Biotechnol; 2018 Sep; 46(6):1230-1235. PubMed ID: 28841806
[TBL] [Abstract][Full Text] [Related]
10. Diclofenac inhibits lactate formation and efficiently counteracts local immune suppression in a murine glioma model.
Chirasani SR; Leukel P; Gottfried E; Hochrein J; Stadler K; Neumann B; Oefner PJ; Gronwald W; Bogdahn U; Hau P; Kreutz M; Grauer OM
Int J Cancer; 2013 Feb; 132(4):843-53. PubMed ID: 22752934
[TBL] [Abstract][Full Text] [Related]
11. A mathematical model of tumor-immune interactions.
Robertson-Tessi M; El-Kareh A; Goriely A
J Theor Biol; 2012 Feb; 294():56-73. PubMed ID: 22051568
[TBL] [Abstract][Full Text] [Related]
12. Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape.
Platten M; Wick W; Weller M
Microsc Res Tech; 2001 Feb; 52(4):401-10. PubMed ID: 11170299
[TBL] [Abstract][Full Text] [Related]
13. TLR2 Promotes Glioma Immune Evasion by Downregulating MHC Class II Molecules in Microglia.
Qian J; Luo F; Yang J; Liu J; Liu R; Wang L; Wang C; Deng Y; Lu Z; Wang Y; Lu M; Wang JY; Chu Y
Cancer Immunol Res; 2018 Oct; 6(10):1220-1233. PubMed ID: 30131377
[TBL] [Abstract][Full Text] [Related]
14. Investigation of immunosuppressive mechanisms in a mouse glioma model.
Ksendzovsky A; Feinstein D; Zengou R; Sharp A; Polak P; Lichtor T; Glick RP
J Neurooncol; 2009 May; 93(1):107-14. PubMed ID: 19430886
[TBL] [Abstract][Full Text] [Related]
15. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.
Eisele G; Wischhusen J; Mittelbronn M; Meyermann R; Waldhauer I; Steinle A; Weller M; Friese MA
Brain; 2006 Sep; 129(Pt 9):2416-25. PubMed ID: 16891318
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: the role of T regulatory cells.
Taylor A; Verhagen J; Blaser K; Akdis M; Akdis CA
Immunology; 2006 Apr; 117(4):433-42. PubMed ID: 16556256
[TBL] [Abstract][Full Text] [Related]
17. Regulatory lymphocytes and intestinal inflammation.
Izcue A; Coombes JL; Powrie F
Annu Rev Immunol; 2009; 27():313-38. PubMed ID: 19302043
[TBL] [Abstract][Full Text] [Related]
18. The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain.
Weller M; Fontana A
Brain Res Brain Res Rev; 1995 Sep; 21(2):128-51. PubMed ID: 8866671
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of foxp3+ T regulatory cell-mediated suppression.
Shevach EM
Immunity; 2009 May; 30(5):636-45. PubMed ID: 19464986
[TBL] [Abstract][Full Text] [Related]
20. The role of regulatory T cells in malignant glioma.
Sonabend AM; Rolle CE; Lesniak MS
Anticancer Res; 2008; 28(2B):1143-50. PubMed ID: 18505050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]